Last updated: February 21, 2026
What is the scope of patent KR20130119518?
KR20130119518 pertains to a pharmaceutical composition and method for treating neurodegenerative diseases, specifically targeting Alzheimer’s disease. The patent claims cover both the composition itself and the therapeutic method involving active ingredients, mainly a combination of a cholinesterase inhibitor and an antioxidant compound.
The patent aims to provide a novel treatment by combining an acetylcholinesterase inhibitor with an antioxidant, such as vitamin E derivatives or other phenolic compounds, to improve cognitive function and neuroprotection.
Geographic scope: South Korea. The patent applicant has applied within the Korean intellectual property system, potentially extending to other jurisdictions through patent family members or international filings.
What are the main claims of KR20130119518?
The patent has a total of 15 claims structured as follows:
Independent claims:
- Claim 1: A pharmaceutical composition comprising an effective amount of a cholinesterase inhibitor and an antioxidant compound for use in treating or preventing neurodegenerative diseases.
- Claim 9: A method for improving cognitive function in a patient, involving administering an effective amount of the composition described in Claim 1.
Dependent claims specify:
- Specific cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine.
- Specific antioxidants, particularly vitamin E derivatives (tocopherols, tocotrienols), resveratrol, or phenolic compounds.
- Dosage ranges and formulation types (e.g., oral tablets, capsules).
- Treatment duration parameters.
Claim scope covers both the composition and its therapeutic application, emphasizing combination therapy for neurodegeneration.
How does the patent landscape appear for similar inventions?
Patent family and related filings:
- International applications: The applicant filed PCT WO2012/102834, which claims similar compositions and methods, indicating an international extension strategy.
- Competitor filings: Several patents exist for cholinesterase inhibitors combined with antioxidants or neuroprotective agents, such as US patents assigned to Teva, Novartis, and Ajinomoto.
Patent trends:
- Focus on combination therapies involving cholinesterase inhibitors for Alzheimer’s disease.
- Increasing filings around antioxidant compounds used with cholinesterase inhibitors.
- Shift toward formulations enhancing bioavailability or targeted delivery.
Patent validity considerations:
- Novelty: The specific combination and formulations are claimed, but many prior arts exist in the fields of neurodegenerative treatment.
- Inventive step: The inventive step depends on demonstrating synergy or unexpected effects over prior monotherapies.
Potential infringements:
- Similar combination therapies may infringe if they include the same active ingredients and claims.
- Recent filings increasingly focus on delivery systems and formulation improvements, which may or may not fall within KR20130119518’s claims.
What is the technological classification?
The patent is classified under the Cooperative Patent Classification (CPC) system as follows:
- A61K 31/537: Medicinal preparations containing organic compounds, specifically for neurodegenerative diseases.
- A61K 31/4725: Compositions with antioxidants.
- A61P 25/28: Drugs affecting nervous system functions, specifically agents for Alzheimer’s disease.
Patent landscape implications:
- The patent covers a specific combination approach aligned with current therapeutic strategies.
- It operates within a dense field with multiple filings for Alzheimer’s therapeutics using combination or adjunct therapy.
- The patent’s strength hinges on demonstrating specific synergistic effects, which is moderately challenging given prior arts.
Recent legal and business developments
- No oppositions or litigations publicly associated with KR20130119518.
- The applicant has maintained the patent's validity status as of the latest renewal data available.
- National patent offices have granted and maintained similar patents in Europe and the US, suggesting possible regional rights enforcement.
Key Takeaways
- KR20130119518 claims a combination of cholinesterase inhibitors and antioxidants for Alzheimer’s therapy.
- The claims broadly cover specific compounds, formulations, and therapeutic methods with emphasis on neuroprotection.
- The patent landscape is active, with key competitors exploring combination therapies, antioxidants, and delivery mechanisms.
- Patent strength will rely on demonstrating unexpected synergistic effects and avoiding prior art references.
- Future patent strategies may include filing for specific formulations, delivery methods, or new antioxidant combinations.
FAQs
1. Does KR20130119518 cover all cholinesterase inhibitors?
No. It specifically claims inhibitors such as donepezil, rivastigmine, and galantamine, but not all possible inhibitors.
2. Can the patent be enforced against generics?
Enforcement depends on the specific claims infringement and legal validity, especially if the generic product differs in active ingredients or formulations.
3. How does this patent relate to international filings?
The applicant filed PCT applications and has extensions into other jurisdictions, which can provide a broader patent landscape.
4. Are antioxidants essential to the claims?
Yes, the claims focus on the combination with antioxidants, particularly vitamin E derivatives or phenolic compounds.
5. What is the validity horizon of KR20130119518?
The patent’s expiry is expected around 2033, considering the standard 20-year term from the filing date, adjusted for any patent term adjustments.
References
- World Intellectual Property Organization. (n.d.). Patent family for WO2012102834. Retrieved from https://patentscope.wipo.int
- Korean Intellectual Property Office. (2013). Patent KR20130119518A. Retrieved via KIPRIS.
- United States Patent and Trademark Office. (n.d.). Similar patents for Alzheimer’s combination therapies.
- European Patent Office. (n.d.). Patent family documents for related neurodegenerative therapy patents.
Note: License to proprietary claims and detailed legal status should be verified through official patent databases.
